Decision-making by healthcare payers

Research output: Contribution to journalArticle

Standard

Decision-making by healthcare payers. / Levine, M; Taylor, Rodney; Ryan, M; Scupher, M.

In: Respiratory Medicine, Vol. 96, 31.12.2002, p. s31-s38.

Research output: Contribution to journalArticle

Harvard

Levine, M, Taylor, R, Ryan, M & Scupher, M 2002, 'Decision-making by healthcare payers', Respiratory Medicine, vol. 96, pp. s31-s38.

APA

Levine, M., Taylor, R., Ryan, M., & Scupher, M. (2002). Decision-making by healthcare payers. Respiratory Medicine, 96, s31-s38.

Vancouver

Levine M, Taylor R, Ryan M, Scupher M. Decision-making by healthcare payers. Respiratory Medicine. 2002 Dec 31;96:s31-s38.

Author

Levine, M ; Taylor, Rodney ; Ryan, M ; Scupher, M. / Decision-making by healthcare payers. In: Respiratory Medicine. 2002 ; Vol. 96. pp. s31-s38.

Bibtex

@article{df4c5bf450fb4c2db19b199e4f2004a3,
title = "Decision-making by healthcare payers",
abstract = "Healthcare payers are faced with the need to allocate finite resources to maximize population health. To assist in decision-making, healthcare payers are increasingly using health outcomes information and economic analyses. Healthcare payers are often under pressure to make early decisions (around the time of product launch), when the evidence available is imperfect. They must also consider the equitable distribution of resources between therapeutic areas. Tools to help healthcare payers reach transparent and objective decisions include cost-utility analysis and decision modelling. In practice, healthcare payers in different countries (for example, Ireland, France and Canada) vary in the approaches taken to reimbursement and formulary listing decisions. The key to decision-making among healthcare payers is the provision of appropriate evidence, comparing any new treatment approach to current best practice, in situations corresponding to real life. When data assumptions have to be made, these should be clearly stated with consideration of the impact of varying the assumptions. The impact on budgets should also be considered.",
keywords = "QALYs, decision models, cost-effectiveness, utility, healthcare payers, chronic obstructive pulmonary disease",
author = "M Levine and Rodney Taylor and M Ryan and M Scupher",
year = "2002",
month = dec,
day = "31",
language = "English",
volume = "96",
pages = "s31--s38",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Decision-making by healthcare payers

AU - Levine, M

AU - Taylor, Rodney

AU - Ryan, M

AU - Scupher, M

PY - 2002/12/31

Y1 - 2002/12/31

N2 - Healthcare payers are faced with the need to allocate finite resources to maximize population health. To assist in decision-making, healthcare payers are increasingly using health outcomes information and economic analyses. Healthcare payers are often under pressure to make early decisions (around the time of product launch), when the evidence available is imperfect. They must also consider the equitable distribution of resources between therapeutic areas. Tools to help healthcare payers reach transparent and objective decisions include cost-utility analysis and decision modelling. In practice, healthcare payers in different countries (for example, Ireland, France and Canada) vary in the approaches taken to reimbursement and formulary listing decisions. The key to decision-making among healthcare payers is the provision of appropriate evidence, comparing any new treatment approach to current best practice, in situations corresponding to real life. When data assumptions have to be made, these should be clearly stated with consideration of the impact of varying the assumptions. The impact on budgets should also be considered.

AB - Healthcare payers are faced with the need to allocate finite resources to maximize population health. To assist in decision-making, healthcare payers are increasingly using health outcomes information and economic analyses. Healthcare payers are often under pressure to make early decisions (around the time of product launch), when the evidence available is imperfect. They must also consider the equitable distribution of resources between therapeutic areas. Tools to help healthcare payers reach transparent and objective decisions include cost-utility analysis and decision modelling. In practice, healthcare payers in different countries (for example, Ireland, France and Canada) vary in the approaches taken to reimbursement and formulary listing decisions. The key to decision-making among healthcare payers is the provision of appropriate evidence, comparing any new treatment approach to current best practice, in situations corresponding to real life. When data assumptions have to be made, these should be clearly stated with consideration of the impact of varying the assumptions. The impact on budgets should also be considered.

KW - QALYs

KW - decision models

KW - cost-effectiveness

KW - utility

KW - healthcare payers

KW - chronic obstructive pulmonary disease

M3 - Article

C2 - 12199490

VL - 96

SP - s31-s38

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -